Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

clinical benefit

This page shows the latest clinical benefit news and features for those working in and with pharma, biotech and healthcare.

New data backs GeNeuro’s MS drug after Servier exit

New data backs GeNeuro’s MS drug after Servier exit

The company thinks this is its best route to showing a clinical benefit and approval.

Latest news

  • Sanofi's Dupixent gains asthma approval in Europe Sanofi's Dupixent gains asthma approval in Europe

    In clinical trials, Dupixent not only reduced exacerbations and oral corticosteroid use, but it also improved lung function and patients' overall quality of life. ... The companies have big plans for the drug, researching its clinical benefit in other

  • Lilly to withdraw Lartruvo, a first for accelerated approval failures Lilly to withdraw Lartruvo, a first for accelerated approval failures

    Lilly says it will present data from the trial at the American Society of Clinical Oncology (ASCO) meeting in June. ... For those that had, eight had not confirmed clinical benefit five years or more after the agency granted accelerated approval.

  • Sangamo surges on data for haemophilia A gene therapy Sangamo surges on data for haemophilia A gene therapy

    Gene therapy stocks can see their values soar or plummet on the back of clinical results in just a handful of patients, and Sangamo was no exception, rising almost 30% in ... well-tolerated and may prove to have the predictability and sustained treatment

  • Positive data unlocks more EIB funding for Nanobiotix Positive data unlocks more EIB funding for Nanobiotix

    as well as an independent assessment of the clinical benefit/risk ratio for NBTXR3 in a phase 3 programme in soft tissue sarcoma (STS). ... This financing will allow us to advance our global development plan and continue the development of NBTXR3, a

  • Lynparza scores against pancreatic cancer Lynparza scores against pancreatic cancer

    The results of POLO provide further evidence of the clinical benefit of Lynparza across a variety of BRCA-mutated tumour types. ... The clinically-meaningful results of this trial potentially support the value of testing for germline BRCA mutations in

More from news
Approximately 1 fully matching, plus 146 partially matching documents found.

Latest Intelligence

  • The European Medicines Agency: PRIME’d for access? The European Medicines Agency: PRIME’d for access?

    The scheme. The PRIME scheme is for medicines that have real promise, defined by the EMA as medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients ... Companies who want to benefit from the scheme have to

  • Can new data aggregators shift the balance of power away from pharma? Can new data aggregators shift the balance of power away from pharma?

    This could have far-reaching consequences for some players in the pharmaceutical industry who may find their product pricing to be untenable when the cost/clinical benefit calculus becomes totally transparent.

  • Patient recruitment and engagement standards Patient recruitment and engagement standards

    And the reality: 50% of clinical research sites don’t recruit a single patient. ... A number of studies have revealed that awareness changes patients’ perceptions about clinical trials, enrolment and the risk/benefit ratio of getting involved.

  • Taking a lean and careful approach Taking a lean and careful approach

    Chemotherapy and Pharmacology, which concluded its treatment regimen showed ‘encouraging clinical benefit’. ... Clinical trials. The company is moving cautiously and set its clinical trials in Israel, Italy, Turkey and Greece.

  • Strengthening market access deliverables by harnessing the patient journey Strengthening market access deliverables by harnessing the patient journey

    Topics such as the clinical value of new products, or what impact the product has on outcomes are relevant to multiple stakeholders. ... management, clinical benefit and economic/humanistic benefit.

More from intelligence
Approximately 0 fully matching, plus 23 partially matching documents found.

Latest appointments

  • Dr Irina Antonijevic joins vasopharm Dr Irina Antonijevic joins vasopharm

    In this role, Dr Antonijevic will be responsible for advancing the clinical development of the cerebrovascular specialist's lead orphan drug candidate, VAS203. ... Not only will we benefit from her clinical capabilities in our ongoing pivotal study of

  • ICON's CEO named chair of ACRO ICON's CEO named chair of ACRO

    Trade body for clinical research organisation elects Ciaran Murray. The global trade body for clinical research organisations has elected ICON's CEO Ciaran Murray as chairman. ... I look forward to continuing the work that ACRO has done in promoting our

  • Industry veteran Louis Nisbet joins Sygnature board Industry veteran Louis Nisbet joins Sygnature board

    The UK-based clinical research organisation (CRO) will benefit from Dr Nisbet's extensive experience in the life sciences industry, which includes spells in research at Roche, Glaxo and SmithKline.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Quick links

Infographics

Multimedia